| Aug 30 |
NeuroSense Therapeutics receives Nasdaq minimum bid price notification
|
| Aug 30 |
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
|
| Aug 28 |
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
|
| Aug 7 |
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
|
| Aug 1 |
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial
|
| Jul 9 |
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
|
| Jul 1 |
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug
|
| Jun 24 |
NeuroSense Therapeutics GAAP EPS of -$0.35 misses by $0.16
|
| Jun 24 |
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
|
| Jun 21 |
NeuroSense receives delisting notice from Nasdaq and intends to appeal
|
